Last Updated On 9/6/2023 7:28:57 AM
This is a disclosure report of the user financial relationships with for-profit health care companies.
All relationships are considered compensated unless otherwise noted. Relationships are self-held unless otherwise noted.
| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: Ankyra Therapeutics |
| Recipient: You |
|
| Honoraria |
| Company: Novartis |
| Recipient: You |
| Company: Takeda Oncology |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: NW Biotherapeutics |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: InterVenn Biosciences |
| Recipient: You |
| Company: Iovance Biotherapeutics |
| Recipient: You |
| Company: Ankyra Therapeutics |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Takeda |
| Recipient: You |
| Company: Olink Proteomics |
| Recipient: You |
| Company: Palleon Pharmaceuticals |
| Recipient: You |
| Company: Takeda Oncology |
| Recipient: You |
| Company: InterVenn Biosciences |
| Recipient: You |
| Company: Teiko Bio |
| Recipient: Your Institution |
| Company: Teiko Bio |
| Recipient: Your Institution |
| Company: Teiko Bio |
| Recipient: Your Institution |
| Company: Teiko Bio |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| Please describe: Microfluidic isolation and characterization of SARS-CoV-2 and COVID-19 related extracellular vesicles.
US Patent Application 2022-311, filed April 18, 2022 |
| Recipient: You |
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| Company: Nektar |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|